Re-Evaluating the Association Between Hormonal Contraception and Breast Cancer Risk

References

• Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66. doi:10.1038/s41572-019-0111-2
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst. 1998;90(18):1371–1388. doi:10.1093/jnci/90.18.1371
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320(8):479–484. doi:10.1056/nejm198902233200802
   PubMed Web of Science ®Google Scholar
• Thürlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–2757. doi:10.1056/NEJMoa052258
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13(11):1141–1151. doi:10.1016/s1470-2045(12)70425-4
   PubMed Web of Science ®Google Scholar
• Fraumeni JF Jr, Lloyd JW, Smith EM, Wagoner JK. Cancer mortality among nuns: role of marital status in etiology of neoplastic disease in women. J Natl Cancer Inst. 1969;42(3):455–468. doi:10.1093/jnci/42.3.455
   PubMedGoogle Scholar
• Clavel-Chapelon F, Gerber M. Reproductive factors and breast cancer risk. Do they differ according to age at diagnosis? Breast Cancer Res Treat. 2002;72(2):107–115. doi:10.1023/a:1014891216621
   PubMed Web of Science ®Google Scholar
• Lambertini M, Santoro L, Del Mastro L, et al. Reproductive behaviors and risk of developing breast cancer according to tumor subtype: a systematic review and meta-analysis of epidemiological studies. Cancer Treat Rev. 2016;49:65–76. doi:10.1016/j.ctrv.2016.07.006
   PubMed Web of Science ®Google Scholar
• Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377(23):2228–2239. doi:10.1056/NEJMoa1700732
   PubMed Web of Science ®Google Scholar
• Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal college of general practitioner’s oral contraception study. BMJ. 2007;335(7621):651. doi:10.1136/bmj.39289.649410.55
   PubMed Web of Science ®Google Scholar
• Lyons TR, O’Brien J, Borges VF, et al. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med. 2011;17(9):1109–1115. doi:10.1038/nm.2416
   PubMed Web of Science ®Google Scholar
• Nichols HB, Schoemaker MJ, Cai J, et al. Breast cancer risk after recent childbirth: a pooled analysis of 15 prospective studies. Ann Intern Med. 2019;170(1):22–30. doi:10.7326/m18-1323
   PubMed Web of Science ®Google Scholar
• Liao PV, Dollin J. Half a century of the oral contraceptive pill: historical review and view to the future. Can Fam Physician. 2012;58(12):e757–e760.
   PubMed Web of Science ®Google Scholar
• Petitti DB, Sidney S. Four decades of research on hormonal contraception. Perm J. 2005;9(1):29–34. doi:10.7812/tpp/04-129
   PubMedGoogle Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347(9017):1713–1727. doi:10.1016/s0140-6736(96)90806-5
   PubMed Web of Science ®Google Scholar
• Gynecologists ACoOa. Mammography and other screening tests for breast problems. Available from: https://www.acog.org/womens-health/faqs/mammography-and-other-screening-tests-for-breast-problems. Accessed March 2, 2023.
   Google Scholar
• Shapiro S, Rosenberg L, Hoffman M, et al. Risk of breast cancer in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen contraceptives. Am J Epidemiol. 2000;151(4):396–403. doi:10.1093/oxfordjournals.aje.a010219
   PubMed Web of Science ®Google Scholar
• Shapiro S. Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol. 2000;151(10):939–945. doi:10.1093/oxfordjournals.aje.a010135
   PubMed Web of Science ®Google Scholar
• Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346(26):2025–2032. doi:10.1056/NEJMoa013202
   PubMed Web of Science ®Google Scholar
• Owen-Smith V, Hannaford PC, Warskyj M, Ferry S, Kay CR. Effects of changes in smoking status on risk estimates for myocardial infarction among women recruited for the Royal college of general practitioners’ oral contraception study in the UK. J Epidemiol Community Health. 1998;52(7):420–424. doi:10.1136/jech.52.7.420
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Colditz GA, Hankinson SE, et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev. 2010;19(10):2496–2502. doi:10.1158/1055-9965.Epi-10-0747
   PubMed Web of Science ®Google Scholar
• Beaber EF, Malone KE, Tang MT, et al. Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomarkers Prev. 2014;23(5):755–764. doi:10.1158/1055-9965.Epi-13-0944
   PubMed Web of Science ®Google Scholar
• Burchardt NA, Eliassen AH, Shafrir AL, et al. Oral contraceptive use by formulation and breast cancer risk by subtype in the nurses’ health study II: a prospective cohort study. Am J Obstet Gynecol. 2022;226(6):821.e1–821.e26. doi:10.1016/j.ajog.2021.12.022
   PubMed Web of Science ®Google Scholar
• Dolle JM, Daling JR, White E, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1157–1166. doi:10.1158/1055-9965.Epi-08-1005
   PubMed Web of Science ®Google Scholar
• Adami HO, Signorello LB, Trichopoulos D. Towards an understanding of breast cancer etiology. Semin Cancer Biol. 1998;8(4):255–262. doi:10.1006/scbi.1998.0077
   PubMed Web of Science ®Google Scholar
• Adami HO, Persson I, Ekbom A, Wolk A, Pontén J, Trichopoulos D. The aetiology and pathogenesis of human breast cancer. Mutat Res. 1995;333(1):29–35. doi:10.1016/0027-5107(95)00128-X
   PubMed Web of Science ®Google Scholar
• Johansson AL, Andersson TM, Hsieh CC, Cnattingius S, Lambe M. Increased mortality in women with breast cancer detected during pregnancy and different periods postpartum. Cancer Epidemiol Biomarkers Prev. 2011;20(9):1865–1872. doi:10.1158/1055-9965.Epi-11-0515
   PubMed Web of Science ®Google Scholar
• Zahl P-H, Mæhlen J. Bias in observational studies of the association between menopausal hormone therapy and breast cancer. PLoS One. 2015;10(5):e0124076. doi:10.1371/journal.pone.0124076
   PubMed Web of Science ®Google Scholar
• Kanadys W, Barańska A, Malm M, et al. Use of oral contraceptives as a potential risk factor for breast cancer: a systematic review and meta-analysis of case-control studies up to 2010. Int J Environ Res Public Health. 2021;18(9):4638. doi:10.3390/ijerph18094638
   PubMed Web of Science ®Google Scholar
• Samson M, Porter N, Orekoya O, et al. Progestin and breast cancer risk: a systematic review. Breast Cancer Res Treat. 2016;155(1):3–12. doi:10.1007/s10549-015-3663-1
   PubMed Web of Science ®Google Scholar
• Strom BL, Berlin JA, Weber AL, et al. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer. Contraception. 2004;69(5):353–360. doi:10.1016/j.contraception.2003.12.015
   PubMed Web of Science ®Google Scholar
• Niemeyer Hultstrand J, Gemzell-Danielsson K, Kallner HK, Lindman H, Wikman P, Sundström-Poromaa I. Hormonal contraception and risk of breast cancer and breast cancer in situ among Swedish women 15–34 years of age: a nationwide register-based study. Lancet Reg Health Eur. 2022;21:100470. doi:10.1016/j.lanepe.2022.100470
   PubMedGoogle Scholar
• Pal N, Broaddus RR, Urbauer DL, et al. Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. Obstet Gynecol. 2018;131(1):109–116. doi:10.1097/aog.0000000000002390
   PubMed Web of Science ®Google Scholar
• MIRENA® (levonorgestrel-releasing intrauterine system). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021225s019lbl.pdf. Accessed March 2, 2023.
   Google Scholar
• Backman T, Rauramo I, Jaakkola K, et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol. 2005;106(4):813–817. doi:10.1097/01.AOG.0000178754.88912.b9
   PubMed Web of Science ®Google Scholar
• Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception. 2011;83(3):211–217. doi:10.1016/j.contraception.2010.11.009
   PubMed Web of Science ®Google Scholar
• Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol. 2014;124(2):292–299. doi:10.1097/aog.0000000000000356
   PubMed Web of Science ®Google Scholar
• Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers. 2021;13(17). doi:10.3390/cancers13174287
   Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845. doi:10.1161/circulationaha.106.642280
   PubMed Web of Science ®Google Scholar
• ORTHO EVRA (norelgestromin/ethinyl estradiol transdermal system). Available from: http://www.janssen.com/us/sites/www_janssen_com_usa/files/products-documents/orthoevrapi_092014.pdf. Accessed March 2, 2023.
   Google Scholar
• NUVARING (etonogestrel/ethinyl estradiol vaginal ring). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021187s012lbl.pdf. Accessed March 2, 2023.
   Google Scholar
• van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72(3):168–174. doi:10.1016/j.contraception.2005.03.005
   PubMed Web of Science ®Google Scholar
• Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol. 2004;190(4Suppl):S5–S22. doi:10.1016/j.ajog.2004.01.061
   PubMedGoogle Scholar
• Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception. 2010;82(3):221–229. doi:10.1016/j.contraception.2010.04.006
   PubMed Web of Science ®Google Scholar
• Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: Royal college of general practitioners’ oral contraception study. Am J Obstet Gynecol. 2017;216(6):580.e1–580.e9. doi:10.1016/j.ajog.2017.02.002
   PubMed Web of Science ®Google Scholar